Robert Bissonnette Selected Research

tapinarof

10/2022	One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
12/2021	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
4/2021	Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
1/2021	Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy.
3/2019	Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
1/2018	Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
4/2010	Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Bissonnette Research Topics

Disease

55	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2022 - 07/2002
30	Atopic Dermatitis (Atopic Eczema) 11/2022 - 03/2010
11	Inflammation (Inflammations) 01/2022 - 01/2013
8	Eczema 05/2022 - 01/2018
7	Pruritus (Itching) 12/2021 - 09/2008
6	Hyperplasia 01/2020 - 10/2017
6	Actinic Keratosis 12/2012 - 07/2002
5	Infections 12/2019 - 09/2009
5	Acne Vulgaris 10/2019 - 11/2010
4	Neoplasms (Cancer) 03/2017 - 01/2004
4	Skin Neoplasms (Skin Cancer) 01/2007 - 01/2004
2	Headache (Headaches) 12/2021 - 07/2010
2	Folliculitis (Sycosis) 12/2021 - 01/2021
2	Nasopharyngitis 12/2021 - 08/2016
2	Necrosis 01/2020 - 03/2015
2	Communicable Diseases (Infectious Diseases) 12/2019 - 01/2019
2	Cicatrix (Scar) 10/2019 - 04/2018
2	Myocardial Infarction 10/2017 - 03/2010
2	Rheumatoid Arthritis 05/2015 - 03/2015
2	Psoriatic Arthritis 05/2015 - 03/2015
2	Alopecia Areata 07/2012 - 12/2003
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2007 - 03/2004
2	Basal Cell Carcinoma (Rodent Ulcer) 01/2007 - 01/2007
1	Contact Dermatitis (Eczema, Contact) 12/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 12/2021
1	Atherosclerosis 10/2021
1	Parakeratosis 01/2020

Drug/Important Bio-Agent (IBA)

9	dupilumabIBA 11/2022 - 01/2019
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
8	Interleukin-17 (Interleukin 17)IBA 04/2021 - 07/2015
8	Adalimumab (Humira)FDA Link 01/2017 - 09/2009
7	tapinarofIBA 10/2022 - 04/2010
7	Prostaglandins AIBA 12/2021 - 09/2006
7	CytokinesIBA 11/2021 - 07/2009
6	Etanercept (Enbrel)FDA Link 03/2017 - 09/2009
5	Pharmaceutical PreparationsIBA 09/2020 - 12/2009
5	Biological ProductsIBA 10/2017 - 09/2004
5	1-phenyl-3,3-dimethyltriazene (PDT)IBA 11/2010 - 07/2002
5	Alefacept (Amevive)FDA Link 12/2009 - 09/2009
4	Ustekinumab (CNTO 1275)FDA Link 11/2021 - 09/2009
4	Interleukin-13IBA 01/2021 - 11/2017
4	Ointments (Pastes)IBA 11/2019 - 09/2008
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 01/2013
4	Monoclonal AntibodiesIBA 07/2015 - 07/2009
4	Aminolevulinic Acid (Levulan)FDA Link 01/2007 - 07/2002
3	LipidsIBA 11/2022 - 01/2018
3	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 10/2022 - 04/2021
3	Janus Kinase 1IBA 07/2021 - 08/2016
3	Janus Kinase InhibitorsIBA 06/2021 - 08/2015
3	Proteins (Proteins, Gene)FDA Link 04/2021 - 09/2006
3	Infliximab (Remicade)FDA Link 01/2021 - 09/2009
3	VaccinesIBA 12/2019 - 01/2019
3	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 11/2019 - 07/2016
3	Adapalene (Differin)FDA LinkGeneric 10/2019 - 04/2018
3	Benzoyl Peroxide FDA LinkGeneric 10/2019 - 04/2018
3	Keratin-16 (Keratin 16)IBA 01/2019 - 01/2018
3	RetinoidsIBA 08/2018 - 09/2009
3	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 10/2017 - 01/2010
2	abrocitinibIBA 10/2021 - 12/2019
2	baricitinibIBA 07/2021 - 06/2021
2	Interleukin-23 (Interleukin 23)IBA 01/2021 - 01/2017
2	Immunoglobulin A (IgA)IBA 09/2020 - 04/2018
2	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2020 - 01/2019
2	ChemokinesIBA 01/2020 - 01/2017
2	Interleukin-22 (IL-22)IBA 01/2020 - 08/2015
2	Immunosuppressive Agents (Immunosuppressants)IBA 12/2019 - 09/2009
2	Janus KinasesIBA 10/2019 - 08/2016
2	Tacrolimus (Prograf)FDA LinkGeneric 09/2019 - 09/2008
2	Calcineurin InhibitorsIBA 09/2019 - 03/2006
2	pimecrolimus (Elidel)FDA Link 09/2019 - 10/2017
2	loricrinIBA 01/2019 - 01/2018
2	Interleukin-4 (Interleukin 4)IBA 01/2019 - 11/2017
2	Filaggrin ProteinsIBA 01/2019 - 01/2018
2	pneumococcal purpura-producing principle (PPPP)IBA 01/2017 - 01/2016
2	tofacitinibIBA 10/2016 - 08/2015
2	Tumor Necrosis Factor InhibitorsIBA 09/2016 - 05/2015
2	Antirheumatic Agents (DMARD)IBA 05/2015 - 03/2015
2	GlucocorticoidsIBA 05/2015 - 05/2015
2	Methotrexate (Mexate)FDA LinkGeneric 03/2015 - 09/2009
2	siplizumabIBA 07/2010 - 07/2009
2	XP-828lIBA 12/2007 - 09/2006
1	ruxolitinibIBA 05/2022
1	spesolimabIBA 01/2022
1	upadacitinibIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 11/2021
1	Abatacept (Orencia)FDA Link 11/2021
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 10/2021
1	Janus Kinase 2IBA 07/2021
1	Transcription Factors (Transcription Factor)IBA 04/2021
1	LigandsIBA 04/2021
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2021
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	AntigensIBA 01/2020
1	InterferonsIBA 01/2020

Therapy/Procedure

21	Therapeutics 05/2022 - 12/2003
6	Photochemotherapy (Photodynamic Therapy) 12/2012 - 01/2004
5	Phototherapy (Light Therapy) 11/2013 - 09/2004
4	Biological Therapy 06/2020 - 07/2009
2	Oral Administration 12/2007 - 09/2006